Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors

Bone Marrow Transplantation volume 49, pages 1246–1247 (2014)Cite this article

Subjects

A Corrigendum to this article was published on 03 September 2014

This article has been updated

Allogeneic transplantation is considered to be a form of adoptive immunotherapy, which is active against haematological malignancies. In the absence of an HLA-identical sibling, patients can be allografted using an unrelated donor.1 After myeloablative regimens, in vivo T-cell depletion by anti-thymocyte (ATG) or anti-lymphocyte globulins has been demonstrated to reduce the probability of GVHD and non-relapse mortality (NRM), without an enhanced risk of relapse.2,3 Reduced-intensity conditioning (RIC) or non-myeloablative regimens were introduced more than 10 years ago,4,5 and several regimens have been used with different characteristics in terms of immunoablation, myeloablation and toxicity. In this study, we report the outcomes of patients who received the same ATG-based RIC (FBA), followed by an unrelated or HLA-identical sibling donor.

From July 2005 to December 2009, we treated 109 patients with haematological malignancies with a RIC regimen, followed by unrelated donor stem cells (alloUD; N=51) or by cells from a HLA-identical sibling (alloSIB; N=58).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Change history

  • 03 September 2014

    This article has been corrected since Online Publication and a corrigendum has also been published

References

  1. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576–4583.

    Article  CAS  PubMed  Google Scholar 

  2. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942–2947.

    Article  CAS  PubMed  Google Scholar 

  3. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855–864.

    Article  CAS  PubMed  Google Scholar 

  4. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048–3054.

    CAS  PubMed  Google Scholar 

  5. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  6. Blaise D, Tabrizi R, Boher JM, Le Corroller-Soriano AG, Bay JO, Fegueux N et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer 2013; 119: 602–611.

    Article  CAS  PubMed  Google Scholar 

  7. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, Devine S et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963–6970.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470–476.

    Article  CAS  PubMed  Google Scholar 

  9. Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009; 15: 1422–1430.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cable C, Buzzeo MP, Schold JD, Khan S, Leather H, Moreb J et al. Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT. Bone Marrow Transplant 2010; 45: 31–37.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Transplantation Program, Marseille, France,

    L Castagna, R Crocchiolo, S Furst, J El-cheikh, A Granata, C Faucher & D Blaise

  2. Biostatistic Department, Marseille, France,

    B Esterni

  3. Lymphoma Program, Marseille, France,

    A Stoppa, R Boubdallah & D Coso

  4. Leukemia Program, Marseille, France,

    N Vey & A Charbonnier

  5. Cell Therapy Unit, Marseille, France,

    C Lemarie & C Chabannon

  6. Aix-Marseille Université, Marseille, France

    C Chabannon & D Blaise

  7. Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France,

    C Chabannon & D Blaise

  8. Institut Paoli Calmettes, Marseille, France,

    C Chabannon & D Blaise

Authors
  1. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Crocchiolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Furst
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J El-cheikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Esterni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Granata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Stoppa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Boubdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Coso
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N Vey
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Charbonnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C Lemarie
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C Faucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Castagna.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castagna, L., Crocchiolo, R., Furst, S. et al. Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors. Bone Marrow Transplant 49, 1246–1247 (2014). https://doi.org/10.1038/bmt.2014.138

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.138

This article is cited by

Search

Advanced search

Quick links